Prelude Capital Management’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q3
Sell
2018
Q2
$291K Buy